Skip to main content
Scientific News

Testing for endocrine disruption existing gaps and recommendations from a CRO perspective

By March 18, 2024No Comments

We are pleased to share the poster our colleague Johannes Völker presented at SETAC in 2023.

Title: “Testing for Endocrine Disruption Existing Gaps and Recommendations from a CRO Perspective

Testing for endocrine disruption is an important part of regulating chemical substance in the EU and USA. Accordingly, contract research organisations (CROs) face a high demand for endocrine testing. Since 2019, IES Ltd has been increasingly conducting key in vivo bioassays out of Level 3 or 4 of the OECD conceptual framework for testing and assessing endocrine disruptors, such as the Fish Short Term Reproduction Assay (FSTRA;OECD 229), the Amphibian Metamorphosis Assay (AMA; OECD 231) or the Fish Sexual Development Test (FSDT; OECD 234). In particular, for the registration of plant protection products, the FSTRA and AMA represent key assays to screen for endocrine disruption.